Initial Experience with Generic Letermovir [Anvimo] in Preventing Cytomegalovirus Reactivation in Hematopoietic Stem Cell Transplant Recipients Who Are at a High Risk of Infection.

Transplantation and Cellular Therapy 2026

View at publisher
Authors: Biju George, Shubham Jain, Nutan Joshi, Mithun Prakash Abraham, Yamuna Naik, R.M. Venkatachalam, Sujith Karumathil, Sharon Anbumalar Lionel, Uday Prakash Kulkarni, Anu Korula, Vikram Mathews, Aby Abraham
DOI: 10.1016/j.jtct.2025.12.829
Cited by: 0

Fields of Study & Subjects

Cytomegalovirus and herpesvirus research Hematopoietic Stem Cell Transplantation Viral-associated cancers and disorders

Publication details

Journal / source
Transplantation and Cellular Therapy
Volume
32
Issue
2
Pages
S553–S553
Publication date
1 February 2026
Language
EN